Overview

• Amycretin, a once-daily tablet, mimics the action of two appetite-regulating hormones, amylin and GLP-1.
• In a Phase 1 trial, participants lost an average of 10.4% to 13.1% of their body weight, significantly higher than the placebo group's 1.1%.
• The study included 124 overweight or obese participants without diabetes, focusing solely on weight loss effects.
• Common side effects were mild to moderate gastrointestinal issues, with better tolerability achieved through stepwise dose escalation.
• Further large-scale and long-term studies are needed before amycretin can be considered for regulatory approval.